Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multi...
The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training.
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
Research Cell Banks Produce Therapeutic Proteins in Just Eight Weeks as Validated in Oral Presentation on Integration of Berkeley Lights’ Beacon Optofluidic Platform with Selexis’ Workflow and Clon...
Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing.
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Pl...
Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
12 of 23
Receive JSR Life Sciences news on your RSS reader.
